Commenting on the development, Mr. Shakthi Nagappan, CEO, ‘BioAsia’ said, “BioAsia’s growing prominence as an influential and industry shaping platform for biotechnology and biopharma has drawn the attention of the regulatory community. Participation of these regulators – a very significant section, who shape the industry, is a boost for the platform and will greatly benefit the participating companies”.
Assistant Country Director (Clinical Research)- U.S. FDA India Office Medical
Medical Assessor in Biological Unit of Licensing Division at MHRA (London, UK)
Minister of Health - The Republic of South Africa
Head of Biotechnology Section, National Pharmaceutical Control Bureau, Pharmaceutical Services Division, Ministry of Health- Malaysia
Deputy Director of Regulatory Affairs at State Institute for Drug Control- Czech Republic
Head of Registration Department, Jordan Food & Drug Administration-
Director, State Health Care Accreditation Agency, Ministry of Health- Republic of Lithuania
Director, STI, Ministry of Environment, Science & Technology- Ghana
Director, International Collaboration & Networks, Swedish Government Agency for Innovation Systems (VINNOVA)- Sweden
Director (Medical Technology & Supplies), Ministry of Health, Sri Lanka
Assistant Secretary of Health, USEC Department of Health, Philippines
Top officials from from DCGI, ICMR, DBT, DST, DoP, etc.
The participating regulators will provide a broader perspective of understanding on the existing regulations pursued in their respective markets and across the globe leading to an in-depth understanding on the existing regulatory frameworks and requirements. This knowledge thereby will benefit the Indian companies interested in expanding their business operations and establishing footprints in these regions through exports, joint ventures, marketing, R&D, etc.
“We are extremely glad that the Ministry of Commerce and Industry through the Pharmaceutical Export Promotion Council of India, recognizing the importance of this effort, has come forward and agreed to support this initiative of ‘BioAsia’” he added.
Commenting further Mr. Deepak Sood, Business Director, Lonza India said, “‘BioAsia’
The regulatory meet, in addition to helping the companies understand the regulations, will also offer a platform for the regulators to converge and deliberate on various aspects of harmonizing the regulations globally. The organizers are confident that the regulators meet, will reemphasize the commitment of ‘BioAsia’ towards achieving positive changes in the biotechnology and biopharmaceutical industry.
Commenting on the event, Dr. PV Appaji, Director General, Pharmexcil said “PHARMEXCIL and the Ministry of Commerce are working extremely hard towards achieving the exports targets of USD 25Bn by 2014-15 from the current level of USD 13.5 Bn. We strongly believe that the presence of top regulators from important export destinations and some new markets during ‘BioAsia’ 2013 will be a great step forward in achieving this goal. The response so far from the Indian Industries towards this activity has been overwhelming and we are expecting more than 200 Indian companies to participate and interact with the regulators”
About BioAsia: ‘BioAsia’ is born with a vision to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the biotechnology industry by offering a vibrant global platform for convergence of the key stakeholders - Biotech & Biopharma Companies, research institutions, academia, investors, service providers, policy makers, regulators and analysts. ‘BioAsia’ is focused in its efforts - to drive the growth of the industry by enabling an effective environment for fostering collaborations, JV’s M&A’s;
About FABA (Federation of Asian Biotech Associations):
Pharmexcil: Pharmaceutical Export Promotion Council (Pharmexcil)
For further information queries please contact
Meeta Singh/Ben Paul Thomas, Perfect Relations @ 9949065300/8790432354